• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Mol Ther . A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice

tetano

Editor, Senior Moderator
Mol Ther


. 2022 Jan 6;S1525-0016(22)00011-9.
doi: 10.1016/j.ymthe.2022.01.011. Online ahead of print.
A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice


Carly M Bliss[SUP] 1 [/SUP], Alec W Freyn[SUP] 1 [/SUP], Tom G Caniels[SUP] 1 [/SUP], Victor H Leyva-Grado[SUP] 1 [/SUP], Raffael Nachbagauer[SUP] 1 [/SUP], Weina Sun[SUP] 1 [/SUP], Gene S Tan[SUP] 2 [/SUP], Virginia L Gillespie[SUP] 3 [/SUP], Meagan McMahon[SUP] 1 [/SUP], Florian Krammer[SUP] 4 [/SUP], Adrian Vs Hill[SUP] 5 [/SUP], Peter Palese[SUP] 1 [/SUP], Lynda Coughlan[SUP] 6 [/SUP]



Affiliations

Abstract

Conventional influenza vaccines fail to confer broad protection against diverse influenza A viruses with pandemic potential. Efforts to develop a universal influenza virus vaccine include refocusing immunity towards the highly conserved stalk domain of the influenza virus surface glycoprotein, hemagglutinin (HA). We constructed a non-replicating adenoviral (Ad) vector, encoding a secreted form of H1 HA, to evaluate HA stalk-focused immunity. The Ad5_H1 vaccine was tested in mice for its ability to elicit broad, cross-reactive protection against homologous, heterologous and heterosubtypic lethal challenge, in a single-shot immunization regimen. Ad5_H1 elicited hemagglutination inhibition (HI[SUP]+[/SUP]) active antibodies (Abs), which conferred 100% sterilizing protection from homologous H1N1 challenge. Furthermore, Ad5_H1 rapidly induced H1 stalk-specific Abs with Fc-mediated effector function activity, in addition to stimulating both CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] stalk-specific T cell responses. This phenotype of immunity provided 100% protection from lethal challenge with a head-mismatched, reassortant influenza virus bearing a chimeric HA, cH6/1, in a stalk-mediated manner. Most importantly, 100% protection from mortality following lethal challenge with a heterosubtypic avian influenza virus, H5N1, was observed following a single immunization with Ad5_H1. In conclusion, Ad-based influenza vaccines can elicit significant breadth of protection in naïve animals and could be considered for pandemic preparedness and stockpiling.
 
Back
Top Bottom